CORE LAB REPORTS FIRST QUARTER 2023 RESULTS:
Core Laboratories (NYSE: CLB) reported Q1 2023 revenue of $128.4 million, reflecting an 11% year-over-year increase. Operating income reached $6.5 million, while adjusted operating income was $14.5 million, maintaining operating margins of 11%. The company's diluted EPS was $0.05, up over 130% year-over-year, with adjusted EPS at $0.19.
Core's operations in Reservoir Description generated $80.2 million in revenue, while Production Enhancement brought in $48.2 million. The company approved a redomestication to the U.S. with a 99.3% shareholder vote. Core anticipates a low-single-digit revenue growth for Q2 2023, projecting revenues between $130 million and $135 million.
- 11% year-over-year revenue growth to $128.4 million.
- Over 130% year-over-year increase in adjusted EPS to $0.19.
- Operating margins maintained at 11%, with a significant recovery in operational performance.
- Successful redomestication to the U.S. with 99.3% shareholder approval.
- Positive market outlook with projected Q2 2023 revenue growth.
- Production Enhancement revenue decreased by 3% sequentially.
- Negative free cash flow of $5.4 million for Q1 2023.
- Economic volatility due to the Russia-Ukraine conflict affecting European operations.
- REVENUE OF
; UP SLIGHTLY SEQUENTIALLY; UP$128 MILLION 11% YEAR-OVER-YEAR - OPERATING INCOME OF
; EX-ITEMS OF$6.5 MILLION , FLAT SEQUENTIALLY; UP OVER$14.5 MILLION 100% YEAR-OVER-YEAR - OPERATING MARGINS, EX-ITEMS, OF
11% , WITH YEAR-OVER-YEAR INCREMENTAL MARGINS EXCEEDING55% - GAAP EPS OF
; EX-ITEMS,$0.05 ; UP OVER$0.19 130% YEAR-OVER-YEAR - RESERVOIR DESCRIPTION INCREMENTAL MARGINS, EX-ITEMS, EXCEEDING
80% SEQUENTIALLY;70% YEAR-OVER-YEAR - SHAREHOLDERS APPROVE REDOMESTICATION TO THE
U.S. - COMPANY ANNOUNCES Q2 2023 QUARTERLY DIVIDEND
Core's CEO,
Core remains intently focused on executing its key financial and operational strategies, including: 1) reducing debt and strengthening our balance sheet, 2) consistently pursuing operational efficiencies, and 3) continuing to introduce new, problem-solving technologies. For the remainder of 2023, Core sees the continuation of a multi-year recovery cycle for the oil and gas industry, led by improvement in both onshore and offshore client activity across our global operations. The
Redomestication to
On
The Redomestication required a shareholder vote for approval, which was conducted through an extraordinary general meeting of the Company's shareholders on
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
During the first quarter of 2023,
Also during the first quarter of 2023, under the direction of a
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional, tight-oil reservoirs in the
During the first quarter of 2023, under the direction of a
Also during the first quarter of 2023, Core entered into a multi-year partnership with
Core's SpectraStim™, SpectraScan®, and PackScan® downhole imaging technologies are gaining wider acceptance for evaluation of deepwater
Liquidity, Free Cash Flow and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the first quarter of 2023, cash used in operations was
- Additional cash used to fund working capital requirements. Growth in receivables is more associated with the timing of sales and invoicing as the U.S. market softened from November through February, followed by strong growth in March. Additionally, the U.S. market is also the largest market the Company serves with its product sales and the temporary slow-down in this market resulted in a build of inventory. Some of the growth in inventory is also attributable to building stock to serve large international projects planned for 2023.
- Cash from operations was used during the first quarter of 2023 to execute facility exit and consolidation plans, which will result in annual savings of more than
.$1,500,000 - Payments for liabilities associated with certain employee retirement plans, and
- Annual prepayment for the Company's corporate insurance programs that would traditionally have occurred in the fourth quarter of 2022.
Core expects cash from operations to strengthen and the Company to generate positive free cash in future quarters. The Company will continue to manage investment in working capital in a period of growth. Core's free cash will continue to be returned to its shareholders via the Company's regular quarterly dividend, as well as being focused towards reducing long-term debt.
At the end of the first quarter of 2023, Core's net debt was
On
On
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promote capital efficiency and is designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric of demonstrating superior ROIC performance relative to the oilfield service companies listed as Core's
Industry and Core Lab Outlook and Guidance
Looking forward, Core sees crude-oil macro fundamentals continuing to support a multi-year recovery cycle for the oil and gas industry. For the remainder of 2023, despite recession concerns for key economies around the world, Core sees supply and demand balance tightening as the year unfolds.
Crude-oil demand for 2023, as forecast by the
Turning to the
As result, Core projects Reservoir Description's second quarter 2023 revenue to increase by low-single digits. Continued volatility with crude-oil trading patterns may impact Core's Reservoir Description segment's international growth within its Russian, Ukrainian and European operations. Production Enhancement segment revenue is estimated to increase by mid-single digits.
Core projects second quarter 2023 revenue to range from
The Company's second quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Second quarter 2023 guidance also assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's first quarter 2023 earnings announcement. The call will begin at
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com. Connect with
CORE LABORATORIES N.V. & SUBSIDIARIES | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
|
|
| vs. Q4-22 | vs. Q1-22 | ||||||||||||
REVENUE | $ | 128,356 | $ | 127,571 | $ | 115,300 | 0.6 % | 11.3 % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 101,528 | 99,816 | 96,952 | 1.7 % | 4.7 % | |||||||||||
General and administrative expense | 16,331 | 8,724 | 12,545 | 87.2 % | 30.2 % | |||||||||||
Depreciation and amortization | 4,044 | 4,073 | 4,557 | (0.7) % | (11.3) % | |||||||||||
Other (income) expense, net | (28) | (660) | 1,637 | NM | NM | |||||||||||
Total operating expenses | 121,875 | 111,953 | 115,691 | 8.9 % | 5.3 % | |||||||||||
OPERATING INCOME (LOSS) | 6,481 | 15,618 | (391) | (58.5) % | NM | |||||||||||
Interest expense | 3,429 | 3,081 | 2,644 | 11.3 % | 29.7 % | |||||||||||
Income (loss) before income taxes | 3,052 | 12,537 | (3,035) | (75.7) % | NM | |||||||||||
Income tax expense (benefit) | 610 | 5,847 | (1,196) | (89.6) % | NM | |||||||||||
Net income (loss) | 2,442 | 6,690 | (1,839) | (63.5) % | NM | |||||||||||
Net income (loss) attributable to non- | 69 | (61) | 49 | NM | NM | |||||||||||
Net income (loss) attributable to Core | $ | 2,373 | $ | 6,751 | $ | (1,888) | (64.8) % | NM | ||||||||
Diluted earnings (loss) per share | $ | 0.05 | $ | 0.14 | $ | (0.04) | (64.3) % | NM | ||||||||
Diluted earnings (loss) per share | $ | 0.05 | $ | 0.14 | $ | (0.04) | (64.3) % | NM | ||||||||
Diluted weighted average common | 47,481 | 46,826 | 46,298 | 1.4 % | 2.6 % | |||||||||||
Effective tax rate | 20 | % | 47 | % | 39 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 80,188 | $ | 78,124 | $ | 74,754 | 2.6 % | 7.3 % | ||||||||
Production Enhancement | 48,168 | 49,447 | 40,546 | (2.6) % | 18.8 % | |||||||||||
Consolidated | $ | 128,356 | $ | 127,571 | $ | 115,300 | 0.6 % | 11.3 % | ||||||||
Operating income (loss): | ||||||||||||||||
Reservoir Description | $ | 2,471 | $ | 6,817 | $ | 361 | (63.8) % | 584.5 % | ||||||||
Production Enhancement | 3,281 | 7,904 | (918) | (58.5) % | NM | |||||||||||
Corporate and Other | 729 | 897 | 166 | NM | NM | |||||||||||
Consolidated | $ | 6,481 | $ | 15,618 | $ | (391) | (58.5) % | NM | ||||||||
"NM" means not meaningful |
CORE LABORATORIES N.V. & SUBSIDIARIES | ||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
(In thousands) | ||||||||||
(Unaudited) | ||||||||||
% Variance | ||||||||||
ASSETS: |
|
| vs. Q4-22 | |||||||
Cash and cash equivalents | $ | 16,285 | $ | 15,428 | 5.6 % | |||||
Accounts receivable, net | 110,699 | 106,913 | 3.5 % | |||||||
Inventories | 67,342 | 60,445 | 11.4 % | |||||||
Other current assets | 33,601 | 28,916 | 16.2 % | |||||||
Total current assets | 227,927 | 211,702 | 7.7 % | |||||||
Property, plant and equipment, net | 102,341 | 105,028 | (2.6) % | |||||||
Right of use assets | 56,663 | 52,379 | 8.2 % | |||||||
Intangibles, goodwill and other long-term assets, net | 206,686 | 209,245 | (1.2) % | |||||||
Total assets | $ | 593,617 | $ | 578,354 | 2.6 % | |||||
LIABILITIES AND EQUITY: | ||||||||||
Accounts payable | $ | 38,366 | $ | 45,847 | (16.3) % | |||||
Short-term operating lease liabilities | 11,073 | 11,699 | (5.4) % | |||||||
Other current liabilities | 46,185 | 45,589 | 1.3 % | |||||||
Total current liabilities | 95,624 | 103,135 | (7.3) % | |||||||
Long-term debt, net | 180,440 | 172,386 | 4.7 % | |||||||
Long-term operating lease liabilities | 43,793 | 38,305 | 14.3 % | |||||||
Other long-term liabilities | 73,609 | 75,574 | (2.6) % | |||||||
Total equity | 200,151 | 188,954 | 5.9 % | |||||||
Total liabilities and equity | $ | 593,617 | $ | 578,354 | 2.6 % |
CORE LABORATORIES N.V. & SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(In thousands) | ||||||||
(Unaudited) | ||||||||
Three Months Ended | ||||||||
2023 | 2022 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net Income (loss) | $ | 2,442 | $ | (1,839) | ||||
Adjustments to reconcile net income (loss) to net cash provided by (used in) | ||||||||
Stock-based compensation | 8,984 | 6,227 | ||||||
Depreciation and amortization | 4,044 | 4,557 | ||||||
Deferred income taxes | 936 | 1,698 | ||||||
Accounts receivable | (4,024) | (2,831) | ||||||
Inventories | (7,126) | (2,498) | ||||||
Accounts payable | (7,078) | 3,693 | ||||||
Other adjustments to net income (loss) | (1,347) | (3,717) | ||||||
Net cash provided by (used in) operating activities | (3,169) | 5,290 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures | (2,208) | (2,297) | ||||||
Proceeds from insurance recovery | — | 583 | ||||||
Other investing activities | 170 | 2,142 | ||||||
Net cash provided by (used in) investing activities | (2,038) | 428 | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (16,000) | (14,000) | ||||||
Proceeds from long-term debt | 24,000 | 15,000 | ||||||
Dividends paid | (466) | (463) | ||||||
Repurchase of common shares | (1) | (1,920) | ||||||
Equity related transaction costs | (1,285) | — | ||||||
Other financing activities | (184) | (1) | ||||||
Net cash provided by (used in) financing activities | 6,064 | (1,384) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 857 | 4,334 | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 15,428 | 17,703 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 16,285 | $ | 22,037 | ||||
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the
Reconciliation of Operating Income (Loss), Net Income (Loss) and Diluted Earnings (Loss) Per Share | ||||||||||||
(In thousands, except per share data) | ||||||||||||
(Unaudited) | ||||||||||||
Operating Income (Loss) | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 6,481 | $ | 15,618 | $ | (391) | ||||||
Stock compensation (1) | 6,515 | (1,868) | 3,850 | |||||||||
Loss on lease abandonment and other exit costs (2) | 641 | — | — | |||||||||
Assets write-down (2) | 1,015 | — | — | |||||||||
Severance and other charges | — | — | 3,332 | |||||||||
Redomestication costs | — | 246 | — | |||||||||
Bad debt | — | — | 810 | |||||||||
Foreign exchange losses (gains) | (144) | 691 | (417) | |||||||||
Excluding specific items | $ | 14,508 | $ | 14,687 | $ | 7,184 | ||||||
Net Income (Loss) | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 2,442 | $ | 6,690 | $ | (1,839) | ||||||
Stock compensation (1) | 5,212 | (1,494) | 3,850 | |||||||||
Loss on lease abandonment and other exit costs (2) | 513 | — | — | |||||||||
Assets write-down (2) | 812 | — | — | |||||||||
Severance and other charges | — | — | 2,666 | |||||||||
Redomestication costs | — | 197 | — | |||||||||
Bad debt | — | — | 648 | |||||||||
Foreign exchange losses (gains) | (114) | 552 | (334) | |||||||||
Impact of higher (lower) tax rate (3) | — | 3,341 | (1,359) | |||||||||
Excluding specific items | $ | 8,865 | $ | 9,286 | $ | 3,632 | ||||||
Diluted Earnings (Loss) Per Share | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 0.05 | $ | 0.14 | $ | (0.04) | ||||||
Stock compensation (1) | 0.11 | (0.03) | 0.08 | |||||||||
Loss on lease abandonment and other exit costs (2) | 0.01 | — | — | |||||||||
Assets write-down (2) | 0.02 | — | — | |||||||||
Severance and other charges | — | — | 0.06 | |||||||||
Bad debt | — | — | 0.01 | |||||||||
Foreign exchange losses (gains) | — | 0.02 | (0.01) | |||||||||
Impact of higher (lower) tax rate (3) | — | 0.07 | (0.03) | |||||||||
Impact on assuming dilution | — | — | 0.01 | |||||||||
Excluding specific items | $ | 0.19 | $ | 0.20 | $ | 0.08 | ||||||
(1) Three months ended | ||||||||||||
(2) Three months ended | ||||||||||||
(3) Three months ended | ||||||||||||
Segment Information | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
Operating Income (Loss) | ||||||||||||
Three Months Ended | ||||||||||||
Reservoir | Production | Corporate and | ||||||||||
GAAP reported | $ | 2,471 | $ | 3,281 | $ | 729 | ||||||
Stock compensation (1) | 4,156 | 2,359 | — | |||||||||
Loss on lease abandonment and other exit costs (2) | 377 | 264 | — | |||||||||
Assets write-down (2) | 958 | — | 57 | |||||||||
Foreign exchange losses (gains) | (188) | 134 | (90) | |||||||||
Excluding specific items | $ | 7,774 | $ | 6,038 | $ | 696 | ||||||
(1) Stock compensation expense recognized pursuant to FASB ASC 718 "Stock Compensation" associated with executives reaching eligible retirement age. | ||||||||||||
(2) Write-down of right of use assets and leasehold improvements and other exit costs associated with consolidation of certain facilities. | ||||||||||||
Return on
Return on
ROIC of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is an important measurement because it represents the cash from operations, in excess of capital expenditures, available to operate the business and fund non-discretionary obligations. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative consideration to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash flow should not be considered a measure of liquidity. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow | |||||
(In thousands) | |||||
(Unaudited) | |||||
Three Months Ended | |||||
Net cash used in operating activities | $ | (3,169) | |||
Capital expenditures | (2,208) | ||||
Free cash flow | $ | (5,377) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-first-quarter-2023-results-301808821.html
SOURCE
FAQ
What were Core Laboratories' Q1 2023 revenues and earnings?
How did Core Laboratories perform year-over-year in Q1 2023?
What adjustments were made to earnings per share in Core Laboratories' Q1 2023 results?
What is the financial outlook for Core Laboratories in Q2 2023?